Black Diamond Therapeutics (BDTX) Operating Expenses (2018 - 2021)
Historic Operating Expenses for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q4 2021 value amounting to $26.1 million.
- Black Diamond Therapeutics' Operating Expenses rose 1249.62% to $26.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was $96.2 million, marking a year-over-year increase of 3821.91%. This contributed to the annual value of $126.9 million for FY2021, which is 8236.6% up from last year.
- Per Black Diamond Therapeutics' latest filing, its Operating Expenses stood at $26.1 million for Q4 2021, which was up 1249.62% from $35.4 million recorded in Q3 2021.
- Black Diamond Therapeutics' Operating Expenses' 5-year high stood at $35.4 million during Q3 2021, with a 5-year trough of $3.0 million in Q4 2018.
- Over the past 4 years, Black Diamond Therapeutics' median Operating Expenses value was $14.0 million (recorded in 2020), while the average stood at $16.5 million.
- In the last 5 years, Black Diamond Therapeutics' Operating Expenses surged by 23959.29% in 2019 and then surged by 1249.62% in 2021.
- Black Diamond Therapeutics' Operating Expenses (Quarter) stood at $3.0 million in 2018, then surged by 239.59% to $10.3 million in 2019, then skyrocketed by 124.12% to $23.2 million in 2020, then grew by 12.5% to $26.1 million in 2021.
- Its Operating Expenses stands at $26.1 million for Q4 2021, versus $35.4 million for Q3 2021 and $34.7 million for Q2 2021.